PR018
CAMBRIDGE BIOSTABILITY AWARDED £200,000 EEDA GRANT TO DEVELOP NOVEL STABLE VACCINE DELIVERY PLATFORM

The Development grant, worth up to £200,000 over 18 months is to be used to further the development of HydRIS from its existing laboratory scale to an automated, self-contained sterile production process making HydRIS units to current good manufacturing practice (cGMP) standards. 

click here for Press Release (18)

 

PR017
CAMBRIDGE BIOSTABILITY APPOINTS LUCA GUERZONI AS
CHIEF EXECUTIVE OFFICER

Cambridge Biostability Ltd (CBL), the developer of temperature stable vaccines, today announced the appointment of Luca Guerzoni as Chief Executive Officer to succeed Dr David Stone with effect from 1 January 2008. Dr Stone is appointed Non-Executive Director and will remain on the Board.

click here for Press Release (17)

 

 

 

 

 

 

 

 

 

 

 

Latest News

syringe

 

 

 

 

Cambridge Biostability has developed the technology to create thermo-stable liquid vaccines, either in single or multivalent forms. Using pioneering, patented methods, vaccines can now be transported anywhere and administered immediately without refrigeration or re-constitution. 

This remarkable development is achieved through the production of glass microspheres containing stabilised vaccine. These microspheres float with neutral buoyancy in a liquid which cannot dissolve them but which is harmless upon injection.

microspheres

When injected into the body, the glass spheres are simply dissolved by the body fluids and the active ingredients are released unchanged and unharmed. And because the microspheres are so highly polished they roll past each other extremely easily causing the suspension to behave as if it had no solid component whatsoever. Therefore there is no possibility of obstruction or jamming of the syringe during injection.

By producing glass microspheres whose densities are closely matched with that of the suspending liquid, the particles neither sink nor float and always remain in suspension, ready for immediate injection.

The potential is huge.

Vaccines that are known to be unstable or difficult to administer can be stabilised and stored in a liquid form ready for immediate use. Multivalent vaccines can be produced to protect patients against many different diseases in one dose. Multi-component vaccines can be developed for biodefence use and stockpiled for many years.

The same technology can be applied to a wide range of drugs that normally need to be refrigerated.  The technology continues to develop.  New discoveries at Biostability have opened up the possibility of slow release of vaccine in the body to prolong the stimulation of immunity.  This has the potential to eliminate or reduce the number of booster injections which are currently required to generate full immunity.

Cambridge Biostability Limited is a limited company registered in England & Wales with registered number 003630055 and having its registered office at Unit 184, Cambridge Science Park, Milton Road, Cambridge, CB4 0GA, UK.

t. +44 (0) 1223 437400
e. info@biostability.com